No Data
No Data
Express News | Coya Therapeutics Inc Files for Shelf of up to 603,136 Shares of Common Stock by Selling Stockholder - SEC Filing
Express News | Rodman & Renshaw Initiates Coverage On Coya Therapeutics With Buy Rating, Announces Price Target of $18
Rodman & Renshaw Maintains Coya Therapeutics(COYA.US) With Buy Rating, Maintains Target Price $18
Rodman & Renshaw analyst Elemer Piros maintains $Coya Therapeutics(COYA.US)$ with a buy rating, and maintains the target price at $18.According to TipRanks data, the analyst has a success rate of 37.3
Coya Gains as Peer-reviewed Data Highlights Potential of ALS Therapy
Express News | Coya Therapeutics Shares Are Trading Higher After the Company Announced the Publication of a Peer-reviewed Manuscript Titled, "A Phase 1 Proof-of-Concept Study Evaluating Safety, Tolerability, and Biological Marker Responses With Combination Therapy...
Coya Therapeutics Announces Publication Of Phase 1 Study On CTLA4-Ig And Interleukin-2 Combination Therapy For ALS In Frontiers In Neurology
Data demonstrates halting of disease progression in patients with Amyotrophic Lateral Sclerosis (ALS) at 24 weeks (6 months) and a consistent reduction in inflammation, oxidative stress, and enhanced
No Data